Using Xinzerun to support the new generation｜CSCO/CRPC-Fosun Cancer Supportive Treatment Summit Forum and Aokangze® Listing Meeting was successfully held

As we all know, China has fully entered an aging socie.
At the same time, due to the combined influence of modern life>
In October 2016, the Central Committee of the Communist Party of China and the State Council issued the "Healthy China 2030" Plan Outline, which for the first time made people's health a strategic goal of priority developme.
The 5-year survival rate increased by 1
In recent years, scientists and clinical researchers have been exploring ways to cure tumo.
Although tumor diseases have not been completely conquered or chronically diseased at this stage, the fruitful results achieved in this field of research are undeniab.
In particular, a series of new anti-cancer drugs have been launched one after another, and the leap-forward development of molecular targeted therapy and immunotherapy has greatly promoted the improvement of patients' living conditions, and the overall survival period has also been greatly prolong.
However, cancer patients have one and only one chance of optimal treatme.
In this era of rapid development of treatment methods, treatment plans, and drug changes, what is the best treatment opportunity for cancer patients? Many experts mentioned that the treatment methods that take into account the prolongation of survival time and the improvement of the quality of life, the early incision of tumor palliative and supportive care, and the establishment of a more perfect whole-course management model for tumor patients should be the best treatment opportunities for today's tumo.
China established the Chinese Anti-Cancer Association Cancer Rehabilitation and Palliative Care Professional Committee in 1994, and in the same year (1994), the term "supportive care" was used for the first time in the wor.
China started early in the field of supportive ca.
With the continuous deepening of research, a series of important progresses have been made in tumor supportive care in various fiel.
The concept of supportive care has gradually become popular, and doctor-patient cognition has gradually changed from the traditional treatment conce.
Transformation, oncology support treatment is once again full of vitali.
Li Shengli, Executive President and Chief Development Officer of Fosun Pharma, mentioned that, as a global pharmaceutical and health industry group rooted in China and driven by innovation, Fosun Pharma pursues the mission of “enjoying health” for every family, and takes innovation and R&D as the core driving for.
Through independent research and development, cooperative development, licensing introduction, and deep incubation, it will carry out all-round expansion around key disease areas such as tumo.
After more than ten years of continuous investment, in the past three years, a number of innovative varieties such as Hanlikang®, Hanquyou®, Sukexin®, Yikaida® (CAR-T cell therapy products) have been approved for the market, Aokangze® A number of excellent products have reached an agreement on cooperation and promotion in Chi.
Especially in the field of tumor support therapy, it is hoped that Fosun Pharma's two outstanding products in this field, Aokangze® and Sukexin®, can help China's non-vomiting management and platelet manageme.
At the same time, in the post-epidemic era, the need for out-of-hospital full-course management has become increasingly promine.
Focusing on the patient, Fosun's large health system will also integrate resources from all parties to jointly contribute to the development of tumor support and palliative ca.
In order to further promote tumor supportive care and advocate the latest treatment concepts, on May 22, 2022, the China Society of Clinical Oncology (CSCO) and the Cancer Rehabilitation and Palliative Care Professional Committee (CRPC) of the China Anti-Cancer Association jointly launched the Fosun Cancer Supportive Care Pe.
The forum and Aokangze® listing meeting kicked off onli.
The meeting specially invited Professor Ma Jun, Director of Harbin Institute of Hematology and Oncology, Professor Qin Shukui, Vice Chairman of China CSCO, and Professor Li Jin, Chairman of Asian Oncology Alliance, as the chairman of the conferen.
Nearly 60 well-known experts from home and abroad participated in the conference and shared exciting contents such as tumor supportive care management, chemotherapy-induced nausea and vomiting (CINV), and tumor treatment-induced thrombocytopenia (CTIT) manageme.
At the beginning of the meeting, Professor Ma Jun introduced that tumor patients often have a series of complications during the treatment process, and the treatment of complications often requires drug treatment, psychological counseling, and external ca.
These supportive therapies account for about half of cancer ca.
Fosun Pharma is based in China and has a global perspecti.
It has introduced two excellent products in the field of supportive care, Sukexin® and Aokangze®, to help patients improve their quality of life in an all-round w.
Professor Qin Shukui mentioned in his speech that in clinical practice, we not only pay attention to the length of life of patients, but also help them adapt to the treatment as much as possible, improve the quality of life, and reduce the adverse reactions related to anti-tumor thera.
Therefore, supportive care is an important part of anti-tumor therapy and should run through the entire process of tumor thera.
In his speech, Professor Li Jin said that today, chemotherapy and some highly toxic molecular targeted drugs are still widely used in clinical practi.
Therefore, the control of toxic and side effects and the improvement of patients' quality of life are important for our docto.
responsibili.

Academician Yu Jinming pointed out in his speech that tumor supportive care is the prevention and management of the tumor itself and the adverse reactions of tumor treatme.

Fosun Pharma has successively launched high-quality therapeutic drugs such as Avatrombopag and Netupitam Palonosetron, which have brought more survival benefits to Chinese patien.

I believe that with the joint efforts of many parties, "Healthy China" will surely come so.
Star-Olympic Departure Session This session is chaired by Professor Wu Depei from the First Affiliated Hospital of Soochow University, Professor Zhang Li from Sun Yat-Sen University Cancer Center, and Professor Zhou Caicun from Shanghai Pulmonary Hospital Affiliated to Tongji Universi.

The road to approval for Oconz.

In this session, Pr.

Luo Suxia from Henan Cancer Hospital, Pr.

Matti Aapro, former chairman of the Multinational Society for Supportive Cancer Care (MASCC), and Pr.

Yang Yunpeng from Sun Yat-Sen University Cancer Center shared their wonderful conte.

Professor Zhang mentioned that cancer supportive care is an indispensable part of tumor treatme.

In addition to the treatment of tumors, the treatment of tumor-related symptoms is also importa.

In this regard, Professor Luo Suxia of Henan Cancer Hospital mentioned that after tumor treatment has entered the era of targeted immunity, supportive treatment runs through the entire course of tumor patien.

In recent years, Chinese oncology clinicians have undergone major changes in their cognition of clinical treatment, with increasing emphasis and increasingly standardized management metho.

Among them, CINV management focuses on preventi.

In recent years, China has continuously promoted the construction of non-vomiting wards, which will inevitably improve the domestic CINV management lev.

 Internationally, the management of CINV has also been constantly changing with the development of the tim.

The conference invited Pr.

Matti Aapro, former chairman of the Multinational Society for Supportive Care in Cancer (MASCC), to share on "the development of international CINV management and current status of treatmen.

Professor Aapro said that CINV is the biggest factor affecting the quality of life of cancer patien.

With the update of international guidelines, the triple regimen of 5-HT3 receptor antagonist + NK-1 receptor antagonist + dexamethasone (5-HT3 RA + NK-1 RA + Dex) is widely used as a CINV prevention regim.
The ultimate goal of guideline development is to reduce the incidence of CINV to "zer.

The current international management of CINV still faces many challenges, such as poor control of delayed nausea and vomiting, low compliance with guidelines, and insufficient use of NK-1 receptor antagonis.

In the future, in order to facilitate the achievement of the goal of "0" CINV, the use of individualized scoring criteria to quantify the risk of CINV in patients is a key directi.

During the meeting, the chairman of CRPC, Professor Zhang Zhang of Sun Yat-Sen University Cancer Prevention Center and Professor Aapro discussed the dosage and usage scenarios of dexamethasone in the CINV prevention progr.

Professor Aapro said that reducing the dosage of dexamethasone as much as possible is our aim Expected, if necessary, the use of small amounts of dexamethasone did not observe a significant effect on immunothera.

Professor Zhou Caicun mentioned that chemotherapy will bring great pain to patients, and Aokangze® will help patients enjoy the treatme.

In this regard, Professor Yang Yunpeng of Sun Yat-Sen University Cancer Prevention Center gave a wonderful sharing on "Aokangze® Approval Road and China's CINV Management Prospect.

Delayed CINV control in China is much lower than acute CI.

The low compliance with the guidelines and the overly complicated prevention programs in the past have led to the current poor management of CINV in Chi.

The results of the Phase III clinical study of Aokangze® in the global and Asian populations showed that only the treatment group of Aokangze® + dexamethasone was compared with aprepitant + 5-HT3 receptor antagonist + dexamethasone (APR + 5- dexamethason.

In the HT3 RA+Dex) treatment group, the same effect of preventing CINV was achieved with fewer dos.

At the same time, the delayed CINV-free treatment rate of the Aokangze®+Dexamethasone treatment group was as high as 96%, with a delay period of 3-5 da.

The daily non-vomiting rate remained above 91%, and the daily non-significant nausea rate was above 8
Its efficacy in preventing delayed-phase nausea was more advantageo.
At present, Aokangze® has been unanimously recommended by domestic and foreign guidelines (CSCO, ASCO, NCCN, MASCC/ESM.

 After the teachers' sharing, more than 60 experts opened the camera screen in order to help more patients get better treatment, extend the length of the patient's life while expanding the width of the patient's life, and help the launch of Aokangz.

Online, witnessed the listing process together, and liked and took pictures onli.

Star-Ze China Session This session is chaired by Pr.

Feng Jifeng from Jiangsu Cancer Hospital, Pr.

Pan Hongming from Shaw Hospital Affiliated to Zhejiang University School of Medicine, and Pr.

Shen Zan from the Sixth People's Hospital affiliated to Shanghai Jiaotong University, focusing on the pharmacological properties of Aokangze® and CINV preventive drugs iterati.

In this session, Pr.

Li Su from Sun Yat-sen University Cancer Center and Pr.

Yang Mingming from Hong Kong Prince of Wales Hospital shared wonderful content respective.

Professor Feng Jifeng said that Aokangze® is a dual-channel compound preparation that inhibits the receptors of 5-HT3 and NK-1, which provides a new perspective for oncologis.

In order to help clinical experts to have a deeper understanding of the pharmacological properties of Aokangze®, Professor Li Su of Sun Yat-Sen University Cancer Center gave a wonderful sharing on "Interpretation of the Pharmacological Properties of Aokangze.

The unique pharmaceutical advantages of Aokangze® were explained from three aspec.
The first is syner.

Aokangze® (netupitamp palonosetron) is the world's first and only dual-channel fixed-dose combination oral compound capsule that simultaneously blocks 5-HT3 and NK-1 recepto.

The second-generation 5-HT3 receptor antagonist palonosetron with unique pharmacology and significant clinical advantages is composed of a new long-acting and highly selective NK-1 receptor antagonist netupita.

In terms of pharmacology, it is currently the only A drug combination with proven synergistic effect, among which Palonosetron has allosteric binding and positive synergistic effect, which can trigger the internalization of 5-HT3 receptors, lastingly inhibit 5-HT3 receptors, and is the only one that can inhibit 5-HT3 receptors 5-HT3 drugs interacting between 5-HT3 receptor and NK-1 receptor pathways, netupitant has a synergistic effect on substance P response inhibition, and has a superimposed effect on NK-1 receptor internalizati.

The mechanism is synergistic, 1+1>2; the second is the long-lasting characteristics of Aokangze®, the half-life of palonosetron is 40 hours, which is significantly longer than the 5-12 hours of the first-generation 5HT3 drugs, and the half-life of netupitant is 96 hours , significantly longer than the 9-13 hours of aprepitant and fosaprepitant, the occupancy of 5-HT3 receptors and NK-1 receptors in the striatum can reach 90%, and its action time is longer than other similar products; the last is simple Convenience, compared to the traditional multi-drug triple antiemetic program, Aokangze® significantly reduces the total number of antiemetic medications, simplifies clinical prescriptions, is convenient to take, reduces wrong and missed doses in preventive medication, improves patient compliance, and reduces or exempts hormone use , to improve compliance with guidelines, taking 1 capsule 1 hour before each chemotherapy cycle can achieve the effect of preventing CINV throughout the cour.

In addition to the pharmacological properties, the clinical data of Aokangze® are also of intere.

Professor Yang Mingming of Prince of Wales Hospital in Hong Kong shared some data on the use of Aokangze® in Hong Kong, and pointed out that the quality of life of cancer patients has been improved with the iteration of CINV prevention drugs, especially after the addition of NK-1 receptor antagonists, the overall improvement of patients , The complete remission rate of acute and delayed CINV is greatly improv.

Aokangze® contains a new generation of NK-1 receptor antagonists - Netupitant, which has a synergistic effect with Palonosetr.
In Hong Kong, in a study led by Professor Yang Mingming on breast cancer patients treated with anthracyclines, the remission rate of delayed-phase CINV in the Aokangze® treatment group was better than that in the aprepitant group, and the overall and delayed-phase Nausea rates were also better in the aprepitant gro.

Overall, the quality of life of patients treated with Aokangze® was significantly improv.

In addition, multiple domestic and foreign studies have confirmed that Aokangze® has good cost-effectiveness, and it can reduce the direct medical cost associated with CINV event manageme.

 In the discussion session, the experts discussed the significance of support and palliative care, the difficulties of CINV management, the optimization of CINV management, and the advantages of Aokangze® in CINV manageme.

Experts say that CINV directly affects the quality of life of patients and the efficacy of dru.

Supportive and palliative care will improve patient tolerance, increase patient compliance with treatment, and ultimately have a benign impact on patient surviv.

CINV management belongs to the category of support and palliative care, and it still has some difficulti.

For example, only some management and observation based on acute vomiting can be carried out at prese.

There are actually some deficiencies in the observation and management of delayed vomiti.

The management of CINV can be optimized through propaganda and education, standardized diagnosis and treatment, and post-hospital manageme.

Aokangze® provides substantial help for the management of CINV, with convenient administration, long duration of action, and better clinical efficacy on delayed emes.

 In addition to CINV, thrombocytopenia is also a common adverse reaction in tumor treatment, which seriously affects the quality of life of patien.
To this end, the management of CTIT was introduced in the star-leadership stage chaired by Professor Yuan Xianglin of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, and Professor Xiong Jianping of the First Affiliated Hospital of Nanchang University, and the guidelines for standardized diagnosis and treatment of CTIT were introduc.

interpret.

In this session, Pr.

Zhang Jun from Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Pr.

Zhao Donglu from Harbin Institute of Hematology and Oncology shared wonderful content respective.

 Professor Yuan Xianglin mentioned that due to the change of tumor treatment mode from traditional treatment to targeted therapy and immunotherapy, the concept of CIT (chemotherapy-induced thrombocytopenia) has been transformed into CT.

In this regard, Professor Zhang Jun of Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine first gave a wonderful sharing on "The Advanced Road of CTIT Management from the Development History of Platelet Drug.

Professor Zhang Jun pointed out that the traditional ascending plate therapy cannot meet the needs of clinical treatment, and it is urgent to develop drugs with definite curative effect, good safety and convenient u.

At present, a number of second-generation thrombopoietin (TPO) drugs have been marketed in China, and the three small molecule TPO receptor agonists are structurally differe.

Toxic group thrombopoietin receptor agonist (TPO-RA), which can ensure the efficacy while taking into account the safe.

Avatrombopag has a rapid onset of action and can be used in 3-5 days for patients with chronic liver disease (CL.

The early response rate and overall response rate are better than other similar products; Avatrombopag has good safety, no clinically significant effect on the pharmacokinetics in special populations such as liver and kidney dysfunction, and has a lower risk of thrombosis; Valtrombopag is easily taken orally and is not subject to dietary restrictio.

 At present, the management of CTIT in China is not standardiz.

Therefore, it is urgent to solve the problem of standardization of CTIT treatme.
In order to promote the standardized diagnosis and treatment of CTIT, Professor Zhao Donglu of Harbin Institute of Hematology and Oncology gave a wonderful sharing on the "Treatment Guidelines for Thrombocytopenia Induced by Tumor Treatment (2022 Edition) and Interpretation of Treatment Progres.

Professor Zhao Donglu said that radiotherapy and chemotherapy, targeted therapy, and immunotherapy can all cause corresponding thrombocytopen.

The 2022 edition of the treatment guidelines for tumor therapy-induced thrombocytopenia expanded the previous definition of CIT to include CTIT, including chemotherapy-induced thrombocytopenia, which is commonly seen in the past, as well as thrombocytopenia caused by radiotherapy, targeted therapy, and immunothera.

This guideline adds TPO-RA drugs to the level II recommendati.

Previous studies have found that TPO-RA has shown good efficacy in CIT, among which avatrombopag has excellent response rate and effective rate da.

In CIT patients, avatrombopag had an effective rate of 81%; in severe refractory patients, avatrombopag also achieved a 65% response ra.

 In the discussion session, the experts discussed the current status and difficulties of CTIT treatment, the prospect of TPO-RA drugs, the content and guiding significance of the 2022 CSCO CTIT diagnosis and treatment guidelin.

Experts pointed out that the current status of CTIT treatment is very serious, even if it is "chemo-free", patients will also experience thrombocytopenia, this is because in addition to chemotherapy, targeted therapy, immunotherapy and various combination therapy will lead to thrombocytopen.

In addition, some severe thrombocytopenias are very difficult to relie.

Therefore, CTIT has always been a major clinical probl.

The current treatment options for CTIT are limit.
Many relevant clinical studies have been done on TPO-RA drugs, and they have been recommended as level II in the 2022 CSCO CTIT guidelin.

Avatrombopag is the latest generation of TPO-RA drug, which has the advantages of rapid onset of action, good safety, convenient oral administration, and no restriction with mea.

In addition, it also has a good safety profile in patients with impaired liver and kidney functi.

Finally, the experts also raised some unexplored questions, such as whether a combination therapy strategy can better address thrombocytopenia? How can the gap in secondary prevention of thrombocytopenia be filled? It is believed that in the near future, with the continuous enrichment of clinical research, the above problems will be solved, and more clinical treatment options will be provid.

 The Star-Protect the Future Star-Protect the Future session was chaired by Professor Wang Xiaojia from the Cancer Hospital Affiliated to the University of Chinese Academy of Scienc.

This session includes the content of two parts: Dancing Together - New Life, Healing Together - Futu.

In the dance-new part, two ovarian cancer patients recounted their painful experiences of CINV and CTIT during chemotherapy, and their journey of supportive treatment with Aokangze® and Sukexin® respective.

Professor Wang Xiaojia mentioned that in the process of anti-tumor, the pain of tumor patients is self-evide.

Among the few treatment opportunities, giving reasonable and effective supportive treatment can not only improve the patient's physical state, but also help the patient overcome the fear of treatment, which not only prolongs the length of the patient's life, but also broadens the breadth of li.

 In the co-healing-future part, the experts discussed the current status of the use of supportive therapy and the direction of future explorati.

The experts said that there are many clinical factors that cause nausea, vomiting and thrombocytopen.

When the disease occurs, the causative factors should be identified first, and then the right medicine should be prescrib.
At present, the principles of treatment of vomiting caused by abdominal and pelvic radiotherapy are basically the same as those of CI.

After treatment, compliance in patients with radiotherapy-induced vomiting was significantly improv.

In the future, Aokangze® can carry out relevant clinical trials in the field of radiotherapy to expand the indicatio.

TPO-RA drugs have been recommended by the 2022 CSCO CTIT diagnosis and treatment guidelines, and future research can focus on CTIT treatment mode (used alone or in combination with previous treatments), treatment timing (to what extent the platelets have decreased, and platelet-raising therapy can be performed) , secondary prevention,e.

After the discussion, Professor Wang Xiaojia concluded that supportive care is an important part of tumor treatme.

The emergence of new drugs, the update of guidelines, and reasonable and standardized preventive measures can protect the lives of patien.

Summary of the conference In the summary of the conference, the chairman of the conference, Professor Ma Jun, made it clear that the launch of Aokangze® has brought a new weapon to the prevention of CI.

At present, Aokangze® has been written into the guideline, and clinicians should follow the guideline close.

Only standardized diagnosis and treatment guided by the guideline can enable patients to achieve a higher clinical cu.

Combination therapy with Sukexin® will be the direction of future exploration, and we look forward to the expansion of Sukexin® real-world research results and new indications in the futu.

At the end of the meeting, Professor Ma expressed his gratitude to Fosun Pharma and the participating experts, and announced the successful conclusion of the meeti.

Future Prospects In recent years, China's tumor supportive treatment has progressed rapid.

There are also still many unmet therapeutic nee.

First of all, at present, my country's emphasis on tumor supportive care management still needs to be further improv.

In the future, it is necessary to actively promote the concept of tumor supportive care to doctors at all levels, and attach importance to supportive care popularization education and policy educati.
Secondly, the level of diagnosis and treatment of supportive care needs to be further improved, and exploring and developing more new drugs and new diagnosis and treatment methods is also one of the future development directions of supportive ca.

Third, the particularity of tumor recurrence and metastasis determines that tumor supportive care needs to be continu.

Supportive care during hospitalization is only the beginning, not the end, of tumor supportive ca.

Nowadays, out-of-hospital management of tumor supportive care has become an increasingly prominent treatment dema.

It is expected that in the future, methods and technologies such as electronic patient management tools, remote follow-up, and big data will be used to empower the development of tumor supportive ca.

Fourth, tumor supportive care is a typical multidisciplinary collaboration model and a typical example of integrative medici.

It is hoped that in the future, disciplinary barriers can be broken and a more complete tumor supportive care system can be establish.

Finally, in terms of management mode, tumor support therapy will gradually form a three-level management mode of "family-community-hospital", but there is still a long way to go to improve the nursing level of grassroots hospitals and families and maintain overall consisten.

Typesetting: XY, Uni Execution: Uni